AIM Vaccine (HKG:6660) applied for clinical trial approval of its mRNA vaccine for herpes zoster or shingles in the US, according to a Sunday filing with the Hong Kong stock exchange.
The application comes as the vaccine's immune indicators were significantly higher compared with the use of international commercially available recombinant subunit control vaccines, the filing said.
There is still no mRNA shingles jab approved for marketing worldwide, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.